Are in­cen­tives nec­es­sary to achieve tri­al di­ver­si­ty? Two re­searchers say yes

Phar­ma com­pa­nies and even Con­gress have made ef­forts over the last year to en­sure clin­i­cal tri­als are more rep­re­sen­ta­tive of the pa­tients they serve — but two re­searchers ar­gue that isn’t enough.

Brigham and Women’s urol­o­gist Thomas Hwang and John’s Hop­kins on­col­o­gy pro­fes­sor Otis Braw­ley opined in a New Eng­land Jour­nal of Med­i­cine piece on Sat­ur­day that achiev­ing di­ver­si­ty in clin­i­cal tri­als will take a com­bi­na­tion of fed­er­al in­cen­tives and reg­u­la­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER